Tony Pang

Dr. Tony Pang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Journal of Surgical Education
Verified
Journal Article
Closed access
BMB.P. Mao
B.P. Mao
MTM.L. Teichroeb
M.L. Teichroeb
TLT. Lee
T. Lee
GWG. Wong
G. Wong
TPTony Pang
Tony Pang
HPH. Pleass
H. Pleass

5 September 2014 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
DYDanson X. W. Yeo
Danson X. W. Yeo
SJSameer Junnarkar
Sameer Junnarkar
SBSunder Balasubramaniam
Sunder Balasubramaniam
YTYen Pin Tan
Yen Pin Tan
JLJee Keem Low
Jee Keem Low
TPTony Pang
Tony Pang

1 June 2015 in Burns
Verified
Journal Article
Closed access
RDRachel D’cruz
Rachel D’cruz
TPTony Pang
Tony Pang
JHJohn G. Harvey
John G. Harvey
Andrew J A HollandAndrew J A Holland
Andrew J A Holland

5 October 2022 in Anz Journal of Surgery
Verified
Journal Article
Closed access
EWEvangeline Phoebe Woodford
Evangeline Phoebe Woodford
HWHannah Mercy Woodford
Hannah Mercy Woodford
AHAmy Hort
Amy Hort
TPTony Pang
Tony Pang
VLVincent Wai To Lam
Vincent Wai To Lam
CNChristopher Bahdah Nahm
Christopher Bahdah Nahm

2 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TPTony Pang
Tony Pang
ZXZhihong Xu
Zhihong Xu
AMAlpha Raj Mekapogu
Alpha Raj Mekapogu
SPSrinivasa Pothula
Srinivasa Pothula
Therese BeckerTherese Becker
Therese Becker
MAMinoti Vivek Apte
Minoti Vivek Apte
Background: Inhibition of hepatocyte growth factor (HGF)/c-MET pathway, a major mediator of pancreatic stellate cell (PSC)−PC cell interactions, retards local and distant cancer progression. This study examines the use of this treatment in preventing PC progression after resection. We further investigate the postulated existence of circulating PSCs (cPSCs) as a mediator of metastatic PC. Methods: Two orthotopic PC mouse models, produced by implantation of a mixture of luciferase-tagged human pancreatic cancer cells (AsPC-1), and human PSCs were used. Model 1 mice underwent distal pancreatectomy 3-weeks post-implantation (n = 62). One-week post-resection, mice were randomised to four treatments of 8 weeks: (i) IgG, (ii) gemcitabine (G), (iii) HGF/c-MET inhibition (HiCi) and (iv) HiCi + G. Tumour burden was assessed longitudinally by bioluminescence. Circulating tumour cells and cPSCs were enriched by filtration. Tumours of Model 2 mice progressed for 8 weeks prior to the collection of primary tumour, metastases and blood for single-cell RNA-sequencing (scRNA-seq). Results: HiCi treatments: (1) reduced both the risk and rate of disease progression after resection; (2) demonstrated an anti-angiogenic effect on immunohistochemistry; (3) reduced cPSC counts. cPSCs were identified using immunocytochemistry (α-smooth muscle actin+, pan-cytokeratin−, CD45−), and by specific PSC markers. scRNA-seq confirmed the existence of cPSCs and identified potential genes associated with development into cPSCs. Conclusions: This study is the first to demonstrate the efficacy of adjuvant HGF/c-Met inhibition for PC and provides the first confirmation of the existence of circulating PSCs.

30 December 2014 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TPTony Pang
Tony Pang
AKAntony Kaufman
Antony Kaufman
JCJulian Choi
Julian Choi
AGAnthony Gill
Anthony Gill
MDMartin Drummond
Martin Drummond
JSJaswinder Samra
Jaswinder Samra
Peroxisome proliferator‑activated receptors (PPARs) are a family of nuclear receptors involved in lipid metabolism and liver response to injury. We hypothesised that differences in the expression of PPARs may reflect differences in the cellular microenvironment of the liver and, consequently, in the behaviour of colorectal liver metastases. Of the 145 patients who underwent hepatectomy for colorectal liver metastases between 1998 and 2007, 103 had adequate tissue for PPAR staining and histological re‑evaluation. The histological characteristics evaluated included sinusoidal dilatation, perisinusoidal fibrosis, ballooning and steatosis. PPAR‑α and ‑γ staining was performed and the results were correlated with clinical and survival data. Lobular inflammation and sinusoidal dilatation were the most common histopathological abnormalities. A total of 50% of the patients were PPAR‑α‑negative and 34% were PPAR‑γ‑negative. More patients exhibited lobular inflammation in the PPAR‑α‑positive group (P=0.023) compared to patients with negative PPAR‑α staining, as seen on the multivariate analysis. PPAR‑γ positivity was associated with oxaliplatin use, surgical margins ≥1 mm and a trend towards a lesser degree of fibrosis. The median follow‑up in this cohort of patients was 48 months. Patients with PPAR‑α staining had a worse overall survival (median, 36 vs. 79 months, P=0.037) compared to those with no PPAR‑α staining. There was no correlation between PPAR‑α or ‑γ positivity and disease‑free survival. In conclusion, PPAR‑α staining is associated with lobular inflammation and worse overall survival in patients with colorectal liver metastases. The exact mechanism underlying this finding remains unclear and further research into the diagnostic and therapeutic implications is required.